Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have begun a new partnership to commercialize, develop, and research an mRNA vaccine for Shingles.
The disease, a form of the varicella-zoster virus, affects about 1 in 3 Americans. It affects people with cancer and those above the age of 50. It causes painful, disfiguring patches. The patient might still experience pain after it resolves. In cases of severe infection, it could cause blindness, deafness, and paralysis.
BioNTech and Pfizer have previously partnered
The companies have previously partnered to create mRNA vaccines for COVID-19, the most widely used globally. Moreover, they collaborated on an Influenza vaccine in 2018.
The clinical trial will start in the second half of 2022. Both companies will co reunite to the cost of development. In addition, Pfizer will commercialize the product globally. However, BioNTech will sell the vaccine in Turkey, Germany, and some developing countries. The companies will also share the profits.
As per the agreement, BioNTech will receive an upfront payment of $225 million from BioNTech. This amount will include $150 million in equity investments and $75 million in a cash payment. BioNTech, on the other hand, will give $25 million to Pfizer for its antigen technology.
Pfizer and BioNTech have also released their COVID-19 pills, Paxlovid. The companies will launch the drug in several U.S territories and states. However, experts argue that the drug could raise ethical questions on who gets the drug first.
A study in Israel shows that the fourth dose of the vaccine could increase immunity
Meanwhile, a study in Israel has found that a fourth dose of the BioNTech-Pfizer COVID-19 vaccine boosts antibodies by five times a week after receiving the vaccine. Naftali Bennet, the prime minister of Israel, states that this shows that a fourth dose of the vaccine could protect people from severe infection by the omicron variant of the disease.
Pfizer and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) have finalized their collaboration transaction. The agreement includes Pfizer’s commercialization of zavegepant and rimegepant outside the U.S. This deal is now in effect following approval from regulatory bodies.
Pfizer is also asking its ancestors to listen to a webcast with its chairman and CE, Albert Bourla, at the 40th Annual J.P Morgan Healthcare Conference.
Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.